Copyright
©The Author(s) 2025.
World J Gastroenterol. Jan 28, 2025; 31(4): 101933
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.101933
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.101933
Figure 1 Gastroesophageal reflux disease incidence in 2019 (per 100000).
GRED: Gastroesophageal reflux disease.
Figure 2 Compensatory mechanisms of sanogenesis during long-term treatment with proton pump inhibitors.
ECL: Enterochromaffin-like; PPI: Proton pump inhibitor; ATP: Adenosine triphosphate.
- Citation: Kotelevets SM. Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs. World J Gastroenterol 2025; 31(4): 101933
- URL: https://www.wjgnet.com/1007-9327/full/v31/i4/101933.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i4.101933